E.d. Bellis

It’s more than a drug — it’s a cultural phenomenon, a Wall Street darling, and a mirror reflecting the cracks in America’s healthcare system. The Ozempic Effect takes you inside the $70 billion GLP‑1 drug boom — from corporate boardrooms to kitchen tables — asking who really benefits when “miracle weight-loss shots” become part of the national identity. Hosted by Sean McGuire, this episode of America’s Healthcare Challenge unpacks four revealing segments: the market earthquake shaking global stocks, the public health gamble behind lifelong prescriptions, the growing class divide over access, and what this all says about American priorities. Featuring insights, data, and uncomfortable questions about money, medicine, and morality — this is the story of a shot that’s rewriting the business of health. Keywords: Ozempic, Wegovy, GLP‑1 drugs, healthcare podcast, obesity treatment, pharma industry, insurance costs, public health, Wall Street, social inequality, Novo Nordisk, Mounjaro, healthcare economics, Ame